Optimising disease models for lung diseases and drug development

Martin Kolb (Hamilton, Canada)

Source: International Congress 2015 – Development and application of new approaches for respiratory disease research

Session: Development and application of new approaches for respiratory disease research
Session type: Lunchtime session
Number: 2814

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Martin Kolb (Hamilton, Canada). Optimising disease models for lung diseases and drug development. International Congress 2015 – Development and application of new approaches for respiratory disease research

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Early interventions with bacterial metabolites to prevent the development of chronic lung diseases Source: International Congress 2018 – Cross-talk in the lung microenvironment: implications for chronic lung disease Year: 2018
Post-viral effects on the susceptibility of developing chronic lung diseases Source: Virtual Congress 2021 – Viral infections trigger chronic lung damage and disease Year: 2021
Barriers to new drug development in respiratory disease Source: Eur Respir J 2015; 45: 1197-1207 Year: 2015
Barriers to new drug development in respiratory disease Source: Eur Respir J 2016; 47: 356-357 Year: 2016
Murine models of cardiovascular damage in lung diseases Source: Eur Respir Monogr 2020; 88: 31-46 Year: 2020
Prediction of chronic lung disease Source: Eur Respir J 2003; 22: Suppl. 45, 139s Year: 2003
Tele-rehabilitation in chronic lung diseases Source: ERS Course 2017 Year: 2017
IL-17 and Th17-cells as markers of disease progression in pediatric allergic diseases. A therapeutic approach in an "in vitro" models Source: Annual Congress 2011 - T-cell subsets Year: 2011
Bioengineered models of human lung disease Source: International Congress 2019 – From 2D to 3D models of human lung disease: novel developments to rebuild the lung Year: 2019
Development of a new calcilytic for the treatment of inflammatory lung disease Source: International Congress 2018 – Basic pharmacology Year: 2018
Senotherapies for chronic lung disease Source: ERS Lung Science Conference 2020 Year: 2020
Biomarker discovery, development, and implementation in interstitial lung diseases Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021
The characteristics of mycobacterioses in patients with chronic lung diseases Source: International Congress 2019 – Airway infection in COPD Year: 2019